Advanced Cell Diagnostics / Bio-Techne  

Newark,  CA 
United States
https://acdbio.com/
  • Booth: 1014

ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine. Based in Silicon Valley, ACD’s products and pharma assay services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1200+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis.

ACD’s RNAscope®platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.

  • Call Toll-free in the US and Canada  +1877 576-3636s                                                                                                                                                     www.acdbio.com/products

Brands: RNAscope® 2.5 HD Duplex Assay, HiPlex Assays, Multiplex Fluorescent V2, Reagent Kits,Catalog Probes,Chromogenic, BaseScope™ Reagent Kits, Duplex Assay


 Videos

ACD RNAscope® in situ Hybridization (ISH) Technology Overview

 Press Releases

  • July 11, 2019

    Bio-Techne Announces Commercial Release Of
    RNAscope® HiPlex Assay: A Multiplex In Situ
    Hybridization Assay For Tissues

    Expanding research tools for Spatial Genomics by combining molecular information with spatial context in one simple assay.

    MINNEAPOLIS, July 11, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics™-branded RNAscope platform with release of the RNAscope HiPlex Assay. The RNAscope platform is an advanced in situ hybridization assay that enables visualization of singlemolecule gene expression with single-cell resolution directly in intact tissues.

    The RNAscope HiPlex Assay enables researchers to gain greater insights into cellular mechanisms and functions by combining a simplistic workflow with the capability of simultaneously detecting up to twelve RNA targets. Comprehensive spatial studies require tools that permit higher multiplexing capabilities with minimal time, simple processing, and quality performance, while conserving precious samples. Such multiplexing cannot be achieved with traditional in situ hybridization techniques. The RNAscope HiPlex Assay utilizes Bio-Techne's patented signal amplification and background suppression technology to deliver unrivalled specificity and sensitivity with optimal signal generation. Using this assay, researchers are able to perform experiments that generate more data per sample with better characterization of the samples, such as identifying specific cell types with known cellular markers, without compromising the morphological features of the tissue in question.

    Jacob Swanson at the Hospital for Special Surgery in New York City, NY, commented, "The RNAscope HiPlex Assay allows a researcher to add histological context to scRNAseq data, which is important for fully understanding the biology of distinct cell populations. Being able to stain a single section of tissue with up to twelve mRNA probes makes the RNAscope HiPlex Assay a powerful tool for distinguishing cell types in situ. I would recommend the RNAscope HiPlex Assay to anyone looking to visualize distinct populations of cells from scRNAseq data in situ."

    Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics Segment, commented, "We are pleased to expand our in situ RNA tissue analysis leadership position with the release of the RNAscope HiPlex Assay. This is a new platform that is built on our proprietary RNAscope core technology. Our aim is to provide researchers with a platform to precisely characterize cells and gain greater understanding of the transcriptome in a complex and heterogeneous tissue environment through higher plexing."

    The RNAscope HiPlex Assay kits from Bio-Techne is intended for research use only.

    About Bio-Techne Corporation (NASDAQ:TECH)


    Contact:
    David Clair
    Investor Relations
    ir@bio-techne.com
    Phone: 646-277-1266

  • Bio-Techne to offer drug discovery researchers new chromogenic detection options for mRNA ISH tissue analysis
    New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform

    NEWS PROVIDED BY
    Roche Diagnostics
    May 06, 2019, 07:00 ET


    I
    NDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX:
    RHHBY) today announced it has expanded its partnership with Bio-Techne by offering drug discovery researchers in the U.S. new chromogenic detection kits for automated in situ hybridization (ISH) tissue analysis.
     

    The new Roche kits include the DISCOVERY mRNA Purple HRP detection kit (RUO) and the DISCOVERY mRNA Teal HRP detection kit (RUO). The
    purple and teal detection kits feature more translucent dyes that are ideal for co-localization studies for mRNA ISH as well as the ability to perform
    immunohistochemistry (IHC) and ISH for protein-RNA co-detection on the same slide. Both kits are designed to be used on the Roche DISCOVERY
    ULTRA staining platform alongside the recently released Advanced Cell Diagnostics (ACD) RNAscope VS Universal HRP Reagent Kit, which offers
    improved signal-to-noise ratio and robustness.

    In addition, Roche's mRNA Duplex AMP kit (RUO) now has an expanded application that enables the new mRNA Teal HRP detection kit to be used
    with Roche's existing mRNA RED detection kit (RUO) for dual mRNA ISH detection. The teal/red combination provides a distinct visual contrast and
    the translucency of the teal dye allows for studying co-expression of mRNA ISH targets, where the resulting teal and red dyes overlap to produce an
    indigo color. This new application is intended to be used with the recently released RNAscope VS Duplex Reagent Kit, which delivers simultaneous in
    situ detection of two mRNA species.


    "Expanding our partnership with Bio-Techne enables Roche to offer scientists a broader suite of tools to expand their tissue research
    capabilities," said Holly Egan, vice president of marketing for tissue diagnostics at Roche Diagnostics Corporation. "Giving researchers the
    opportunity to automate these assays on a Roche platform helps them save time and generate data faster to accelerate drug discovery research."

    The new detection kits and dual mRNA ISH application enable researchers to increase their multiplexing possibilities, optimize staining conditions for
    challenging antibodies and probes, easily run complex assays, conserve tissue samples and save time.

     

    "We're pleased to partner with Roche to provide researchers access to a fully automated, optimized solution for the performance of RNAscope, our
    highly sensitive and speci􀁾c RNA ISH technology for the detection of any RNA in any species," said Kim Kelderman, president of Diagnostics and
    Genomics at Bio-Techne Corporation. "The expanded chromogenic detection options on the Roche platform provide our customers with
    exceptional visualization and 􀁿exibility for RNAscope staining and ISH-IHC co-staining."

     

    Widely used in cancer research, ISH and IHC tissue-staining methods provide information that helps researchers better understand mechanisms
    of disease and accelerate drug development. Automating ISH and IHC on the DISCOVERY ULTRA platform enables scientists to generate
    standardized, reproducible results and eliminate over 90 percent of manual processes so they can spend more time focusing on their research.

     

    The mRNA ISH detection kits from Roche are intended for research use only on the DISCOVERY ULTRA platform with the ACD RNAscope reagent
    kits from Bio-Techne.

    About Bio-Techne
    Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality puri􀁾ed proteins and reagent solutions -
    notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and
    T-Cell activation technologies. Bio-Techne's portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering
    researchers ef􀁾cient and streamlined options for automated western blot and multiplexed ELISA work􀁿ow. These reagent and protein analysis
    solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also
    develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other
    reagents for OEM and clinical customers. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for
    research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the
    ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and
    Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means
    for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in
    fiscal 2018 and has over 2,100 employees worldwide.

    About Roche
    Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of
    pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right
    treatment to each patient in the best way possible.  

    Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology
    and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a
    frontrunner in diabetes management. 

    Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society.
    The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by
    Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and
    cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognized as the most sustainable company in the Pharmaceuticals
    Industry by the Dow Jones Sustainability Indices (DJSI).

    The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018,
    Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche
    Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. 

    For more information, please visit www.roche.com or diagnostics.roche.com.

    All trademarks used or mentioned in this release are protected by law.


    The DISCOVERY mRNA Purple HRP detection kit (RUO), the DISCOVERY mRNA Teal HRP detection kit (RUO), the mRNA RED detection kit (RUO), the mRNA Duplex AMP kit (RUO), and the DISCOVERY ULTRA system are for research use only. Not for use in diagnostic procedures.

    For more information, please contact:
    Mike Weist
    Roche Diagnostics Corporation
    Indianapolis, Indiana USA
    1 317 371 0035
    mike.weist@roche.com

    SOURCE Roche Diagnostics

  • Bio-Techne and NanoString Partner to Co-Develop Integrated Workflow for RNA Spatial Profiling

    -- Integrated Workflow Combines NanoString's GeoMx DSP High-Plex RNA Assays and Bio-Techne's Highly Sensitive RNAscope Imaging Reagent Portfolio --

    MINNEAPOLIS, March 28, 2019 /PRNewswire/ -- Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and
    molecular diagnostic products, are partnering to accelerate the development of new tools for spatial genomics. The combined workflow that unites the RNAscope® reagent portfolio from Bio-Techne with NanoString's GeoMx™ RNA Assays enables researchers to molecularly guide their high-plex spatial analyses with single cell resolution. The combination will be the basis of an ongoing partnership which is aimed at further integration of these platforms into one concise workflow. These technologies are showcased in a white paper available at the American Association of Cancer Research (AACR) conference being held March 29th - April 3rd, 2019, in Atlanta, GA.

    The combination of Bio-Techne's RNA imaging and NanoString's RNA spatial profiling technology creates compelling value for spatial genomics applications. The synergies in the chemistry and workflow create two key advantages. First, unlike antibodies, RNAscope reagents are universal and can image any known transcript. This
    enables nearly endless combinations of key transcripts that can be imaged to select regions of interest for spatial genomics profiling using GeoMx DSP. Second, GeoMx DSP offers the only high-plex RNA spatial profiling chemistry that is compatible with FFPE. By combining with Bio-Techne's high sensitivity FFPE compatible RNAscope reagents, spatial genomics applications can be extended from basic research to translational and clinical applications.

    The new partnership leverages the power of RNAscope reagents for visualizing molecular RNA targets, and GeoMx DSP data for high-plex profiling and quantification of RNA. Under the terms of the agreement, NanoString and Bio-Techne will develop, validate, and co-market protocols that combine RNAscope reagents and GeoMx assays. In addition, NanoString will provide RNAscope research services through its GeoMx DSP Technology Access Program (TAP). Customers will be able to select from a menu of RNAscope reagents to be combined with the GeoMx highplex RNA spatial profiling assay. 

    "Understanding the tissue microenvironment at the cellular and system level enables researchers to gain insights into tissue function and mechanisms as related to normal development as well as mechanism of disease. Bio-Techne, through its RNAscope portfolio, provides tools to advance this understanding. By partnering with
    NanoString, we believe we can create extremely powerful workflows to accelerate our customers' research," said Kim Kelderman, president, Diagnostics and Genomics Segment for Bio-Techne.

    "This partnership brings together two best-in-class assays that enable imaging and profiling in difficult sample types like FFPE. It provides researchers with the most complete and integrated solution available for RNA biomarkers," said Brad Gray, president and CEO of NanoString. "We are excited to work with the Bio-Techne team, who brings a wealth of experience in developing high resolution, high sensitivity assays for visualizing RNA."

    GeoMx Digital Spatial Profiling

    GeoMx DSP enables high throughput multiplex spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The full launch of the GeoMx DSP platform is scheduled to take place at the upcoming AACR meeting being held March 29 - April 3, 2019, and over 30 systems have already been pre-ordered. At AACR 2019, 13 posters will be presented featuring spatial applications using GeoMx DSP; 10 of the posters will be presented by customers, collaborators and GeoMx DSP beta sites. 

    About Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers.

    Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.

    About NanoString Technologies, Inc.

    NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 2,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to
    easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx™ Digital Spatial Profiler enables
    highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.


    For more information, please visit www.nanostring.com.

    NanoString, NanoString Technologies, the NanoString logo, nCounter, GeoMx and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. RNAscope is a registered trademark of Advanced Cell Diagnostics, Inc. Bio-Techne is a registered trademark of the Bio-Techne Corporation.

    Contact:
    David Clair
    Senior Vice President, Investor Relations
    ir@bio-techne.com
    Phone: 646-277-1266
    Doug Farrell
    Vice President, Investor Relations & Corporate Communications
    dfarrell@nanostring.com
    Phone: 206-602-1768

    View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-andnanostring-partner-to-co-develop-integrated-workflow-for-rna-spatial-profiling-300820245.html

    SOURCE Bio-Techne Corporation


 Products

  • RNAscope® HiPlex Assay
    Higher plexing of up to 12 different RNA targets is enabled by employing cleavable fluorophores and iterative detection with the RNAscope® HiPlex8 Detection kit, and the RNAscope® HiPlex12 Ancillary Kit....

  • RNAscope® HiPlex assay to expand your in situ hybridization potential. Now allowing simultaneously detection of up to 12 different RNA targets per slide mounted sample.

    RNAscope® HiPlex assay requires the reagent kit in conjunction with user specified target probes which contain a mixture of short oligonucleotides designed to bind to a specific target RNA. Each target probe must be assigned to a different probe tail/type (T1-T12). After a series of highly effective and specific signal amplifications, the signal is detected iteratively, where a single RNA transcripts for up to four target genes at a time is visualized as punctate dots in four distinct fluorescent channels. The assay uniquely employs the cleavable versions of fluorophores AF488, Atto550, Atto647 and AF750, the iterative process is to be repeated until all 12 targets are detected. The fluorophore cleaving procedure is rapid with minimal/no effect on RNA and tissue morphology and is independent from a probe stripping protocol. Images from various rounds can be merged together using RNAscope® HiPlex Image Registration Software.

    To view the product information visit: RNAscope HiPlex Assay

    For more information visit:  Advanced Cell Diagnostics

  • Pharma Assay Services
    Pharma Assay Services provides RNAscope® and BaseScope™ in situ hybridization (ISH) services to support pre-clinical and clinical studies for pharma and biotech partners globally, with years of experience in every step of the drug development process....

  • Pharma Assay Services team of specialists, scientists, and pathologists provide unparalleled expertise to ACD’s ISH platforms and ensures that you will have confidence in the science, data, and research conclusions. We Offer:

    Target validation: Screen and validate candidate targets by assessing target expression levels in drug-treated vs naïve samples or disease vs normal tissues

    Biomarker assay development: Evaluate candidate biomarker expression and establish assay performance and dynamic range using bioanalytical method validation guidelines

    AAV biodistribution: Profile the biodistribution of AAV vector together with genetically modified transgenes within the tissue context

    CAR/TCR biodistribution and function: Visualize the biodistribution of CAR-T or TCR-T cells within the tumor microenvironment and assess functionality with co-detection of immune cell markers or markers of activation

    Safety/toxicology tissue screening: Single-molecule detection for high sensitivity screening of normal tissues for pre-clinical ADME and safety assessment

    CDx assay development: Partner with ACD to support the assay feasibility, proof of concept, and validation steps of your RNAscope CDx development efforts

    For more information: Pharma Assay Services 

  • RNAscope® Applications
    At ACD, we offer a revolutionary assay, capturing gene expression in situ at a single cell level which can be visualized within intact tissue. This provides molecular detection in a morphological context to better understand cell-to-cell interactions....

  • About RNAscope® Technology

    The revolutionized RNA in situ detection platform

    Although in situ RNA detection techniques (ISH and FISH) have been around for years, they are largely ineffective. They lack robustness and sensitivity to reliably detect the expression of most human genes. Microarray and PCR are gold standard molecular methods for disease profiling, but clinically relevant information regarding cellular and tissue context, as well as spatial variation of the expression patterns, is lost in the process.

    Inspired to solve these challenges, ACD scientists revolutionized the RNA in situ hybridization method and in 2011 introduced RNAscope® ISH for detection of target RNA within intact cells. The assay represents a major advance in RNA ISH approaches, with its proprietary probe design that simultaneously amplify target-specific signals and suppress background noise from non-specific hybridization. Known for its sensitivity and specificity,  RNAscope® ISH is now a proven technology that has been featured in over 850 publications across a multitude of research areas. ACD offers both comprehensive Pharma Assay Services and Products for the assay to be conducted in research labs: kits, accessories and catalog probes for over 15,000 targets in over 140 species.

    Get familiar with RNAscope® ISH: 

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.